Rokos Capital Management (UK)’s Caribou Biosciences CRBU Stock Holding History

Rokos Capital Management (UK)’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-840,630	Closed	-$1.37M	–	82
2024 Q2	$1.37M	Hold	840,630	–	–	0.01%	95
2024 Q1	$4.3M	Hold	840,630	–	–	0.02%	81
2023 Q4	$4.8M	Sell	840,630 -1,907,509	-69%	-$9.43M	0.04%	57
2023 Q3	$13.3M	Hold	2,748,139	–	–	0.1%	66
2023 Q2	$11.2M	Hold	2,748,139	–	–	0.11%	53
2023 Q1	$14.1M	Hold	2,748,139	–	–	1.04%	23
2022 Q4	$17.3M	Buy	2,748,139 +840,630	+44%	+$7.48M	0.76%	26
2022 Q3	$20.8M	Hold	1,907,509	–	–	0.62%	33
2022 Q2	$10.6M	Buy	1,907,509 +1,058,175	+125%	+$8.09M	0.31%	50
2022 Q1	$7.9M	Buy	849,334 +278,975	+49%	+$2.94M	0.37%	40
2021 Q4	$8.6M	Buy	570,359 +220,386	+63%	+$4.29M	0.52%	21
2021 Q3	$8.2M	Buy	+349,973	New	+$8.56M	0.18%	38

Other funds holding CRBU

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Rokos Capital Management (UK)'s CRBU Position: Q3 2024 in Review

Rokos Capital Management (UK) sold out of Caribou Biosciences (CRBU) in Q3 2024, closing a stake of 840,630 shares — an estimated $1.37M sold.

Rokos Capital Management (UK) first reported a position in CRBU in Q3 2021 and held it in 12 quarters. The position peaked at $20.8M in Q3 2022. 129 funds tracked by Wall St. Rank hold CRBU as of Q3 2024.

Rokos Capital Management (UK) reported no remaining Caribou Biosciences position as of Q3 2024 after selling out during the quarter.
Rokos Capital Management (UK) sold 840,630 Caribou Biosciences shares in Q3 2024, an estimated $1.37M.
Rokos Capital Management (UK) first reported a position in Caribou Biosciences in Q3 2021 and held it in 12 quarters.
Rokos Capital Management (UK)'s Caribou Biosciences position peaked at $20.8M in Q3 2022.
129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2024.

Based on Rokos Capital Management (UK)'s 13F filing for Q3 2024, filed 14 Nov 2024.